https://scholars.lib.ntu.edu.tw/handle/123456789/494975
標題: | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer | 作者: | Lu S Cheng Y Zhou C.-C Wang J Chih-Hsin CHIH-HSIN YANG Zhang P.-H Zhang X.-Q Wang X Orlando M Wu Y.-L. |
關鍵字: | IPD; NSCLC; ORR; PFS; SWT | 公開日期: | 2016 | 出版社: | Elsevier Inc. | 卷: | 17 | 期: | 5 | 起(迄)頁: | e103-e112 | 來源出版物: | Clinical Lung Cancer | 摘要: | We performed a meta-analysis with maximum individual patient data from three phase 3 trials with data available for an elderly East Asian population to compare therapy with a pemetrexed plus platinum doublet with other platinum-based doublets as first-line treatment for nonsquamous non–small-cell lung cancer patients. Consistent with all-age East Asians, better tumor response and tolerability supports a preference for pemetrexed/platinum in elderly East Asians. Background Pemetrexed plus platinum has become a standard of care in first-line treatment for patients with advanced nonsquamous non–small-cell lung cancer. However, elderly lung cancer patients are generally understudied and undertreated in clinical practice in East Asia because of safety concerns. This analysis aimed to provide a picture of the clinical benefit of pemetrexed/platinum in the first-line setting for elderly (age ≥ 65 years) East Asian patients. Patients and Methods Individual patient data from 3 randomized controlled phase 3 trials that enrolled East Asian patients were analyzed in this meta-analysis. Results In elderly East Asian patients (63 in the pemetrexed/platinum group and 42 in the control group), pemetrexed/platinum treatment achieved more benefits compared to other platinum-based doublets, including better overall response rate (32.8% vs. 7.5%), favorable progression-free survival (not statistically significant in adjusted hazard ratio), and significantly longer (3.15 vs. 1.54 months) survival without drug-related grade 3/4 toxicity. Overall survival was numerically prolonged (16.33 vs. 13.77 months; not statistically significant). These benefit trends were similar to those in all-age East Asian patients. In elderly East Asians, pemetrexed/platinum treatment was also associated with a lower incidence rate of drug-related grade 3/4 adverse events. The adverse event profile was similar to that in all-age East Asians. There were no unexpected adverse events. Conclusion Pemetrexed/platinum had good efficacy and also resulted in better overall response and tolerability than other platinum-based doublets as first-line treatment in nonsquamous non–small cell lung cancer in elderly East Asians, which was consistent with data observed in all-age East Asians. ? 2016 The Authors |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969645611&doi=10.1016%2fj.cllc.2016.04.003&partnerID=40&md5=6301e640e1065db48dba653359545805 https://scholars.lib.ntu.edu.tw/handle/123456789/494975 |
ISSN: | 1525-7304 | DOI: | 10.1016/j.cllc.2016.04.003 | SDG/關鍵字: | carboplatin; cisplatin; docetaxel; gemcitabine; granulocyte colony stimulating factor; granulocyte macrophage colony stimulating factor; pemetrexed; antineoplastic agent; pemetrexed; platinum derivative; advanced cancer; aged; anemia; anorexia; Article; cancer survival; drug safety; East Asian; fatigue; febrile neutropenia; hazard ratio; human; laboratory test; leukopenia; lymphocytopenia; meta analysis; multiple cycle treatment; neutropenia; non small cell lung cancer; overall survival; phase 3 clinical trial (topic); progression free survival; randomized controlled trial (topic); systematic review; thrombocytopenia; treatment response; vomiting; Asian continental ancestry group; Carcinoma, Non-Small-Cell Lung; comparative study; disease free survival; female; Lung Neoplasms; male; pathology; survival rate; treatment outcome; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Pemetrexed; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。